Deepa Baswaraj
Cardiovascular Disease · Columbia, MONPI 1033604053
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $1,823 of the $2,186 with a category attached, or 83.4%. 14 manufacturers reported payments, led by Medtronic at 25.1% of the total. Reporting peaked in 2021 at $685 and has fallen 64.7% since, to $242 in 2025. That places this record below the midpoint for cardiovascular disease clinicians in MO, where the typical reported total is $1,720.
Across 91 payments — averaging $24.03 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$548
- Amgen$424
- ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$344
- Novartis$213
- E.r. Squibb & Sons, L.L.C.$208
- AstraZeneca$174
- plus $275 from 8 others
What the payments were for
- Food & beverage$1,82383%
- Education$36317%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic | 10 | $548 |
| Amgen | 16 | $424 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 20 | $344 |
| Novartis | 17 | $213 |
| E.r. Squibb & Sons, L.L.C. | 10 | $208 |
| AstraZeneca | 3 | $174 |
| Johnson & Johnson | 5 | $82 |
| Janssen Scientific Affairs, LLC | 1 | $45 |
| Chiesi USA, Inc. | 2 | $38 |
| Alnylam Pharmaceuticals Inc. | 2 | $34 |
| ZOLL Circulation Inc | 2 | $22 |
| Daiichi Sankyo Inc. | 1 | $22 |
| Pfizer | 1 | $18 |
| Cordis US CORP. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$2,186 in reported general payments places this provider in the 50th percentile of 391 cardiovascular disease providers in Missouri.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Metoprolol Succinate | 13 | $220 |
| Carvedilol | 32 | $172 |
| Atorvastatin Calcium | 17 | $142 |
| Lisinopril | 14 | $98 |
| Spironolactone | 12 | $42 |
| Amlodipine Besylate | 17 | $32 |
| Losartan Potassium | 15 | $31 |
Paid to pharmacies, not to this prescriber.
Other cardiovascular disease in Columbia
- James FairlambColumbia$342K
- Renee SullivanColumbia$18K
- Chirag BavishiColumbia$16K
- Mikhail KosiborodKansas City$1.1M
- Georges ChahoudSaint Louis$937K
- William BowenSaint Louis$726K
- Daniel KellySaint Louis$582K
- John SpertusKansas City$360K
- James EllisonChesterfield$267K
- Osler Jay GuzonSaint Louis$211K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.